Advantage lands NIA funding to advance repurposed Alzheimer’s drug

Company targets confirmatory trials of immunomodulator shown to slow cognitive decline when used as a control arm. Longevity biotech Advantage Therapeutics has secured a $2.5 million Phase II Small Business Innovation Research grant from the National Institute on Aging to advance its Alzheimer’s disease candidate AD04. The Miami-based biotech is preparing to launch confirmatory Phase […] The post Advantage lands NIA funding to advance repurposed Alzheimer’s drug appeared first on Longevity.Technology.